Drug Price Trends for PLAQUENIL

Best Wholesale Price for PLAQUENIL

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
PLAQUENIL 200MG TAB	Amdipharm Limited	59212-0562-10	100	622.64	6.22640	EACH	2023-01-01 - 2026-09-28	Big4
PLAQUENIL 200MG TAB	Amdipharm Limited	59212-0562-10	100	1177.66	11.77660	EACH	2023-01-01 - 2026-09-28	FSS
PLAQUENIL 200MG TAB	Amdipharm Limited	59212-0562-10	100	777.01	7.77010	EACH	2021-09-29 - 2026-09-28	Big4

Plaquenil: Market Dynamics and Price Forecast

Last updated: February 17, 2026

Plaquenil (hydroxychloroquine sulfate) is an antimalarial and anti-inflammatory drug with established markets for rheumatoid arthritis and systemic lupus erythematosus. Emerging research has explored its use in other indications, though its efficacy and safety in these new contexts remain under scrutiny. Patent expirations and the development of biosimil or generic alternatives will significantly influence future market dynamics and pricing.

What is the Current Market Landscape for Plaquenil?

The current market for Plaquenil is primarily driven by its established therapeutic uses.

• Key Indications:
  • Rheumatoid Arthritis (RA): Plaquenil is a second-line treatment for RA, often used to manage joint inflammation and pain.
  • Systemic Lupus Erythematosus (SLE): It is a standard therapy for SLE, helping to control skin manifestations and systemic disease activity.
• Market Size: The global market for hydroxychloroquine was estimated to be approximately $600 million in 2023 [1]. This figure encompasses branded Plaquenil and generic versions.
• Geographic Distribution: North America and Europe represent the largest markets due to higher prevalence of autoimmune diseases and established healthcare systems. Asia-Pacific is a growing market with increasing access to healthcare and a rising incidence of autoimmune disorders.
• Competitive Landscape: The market is characterized by the presence of Sanofi, the originator of Plaquenil, alongside numerous generic manufacturers. The availability of lower-cost generic options exerts downward pressure on prices, particularly in developed markets.
• Key Market Drivers:
  • Increasing prevalence of autoimmune diseases like RA and SLE globally.
  • Growing awareness and diagnosis of these conditions.
  • Long-standing clinical use and physician familiarity with Plaquenil.
• Market Restraints:
  • Patent expiries leading to increased generic competition.
  • Potential for off-label use investigations and subsequent regulatory scrutiny.
  • Development of newer, more targeted therapies for autoimmune diseases that may offer superior efficacy or safety profiles.
  • Historical controversies and public perception shifts related to its use in other, unproven indications.

What are the Patent Expirations Affecting Plaquenil?

The patent landscape for Plaquenil is largely characterized by the expiry of its primary composition of matter patents, opening the door for generic competition.

• Original Composition of Matter Patents: The foundational patents protecting hydroxychloroquine sulfate as a chemical entity have long expired. This allowed for the introduction of generic hydroxychloroquine sulfate in many regions decades ago.
• Secondary Patents: While primary patents have expired, there may have been secondary patents related to specific formulations, manufacturing processes, or methods of use. However, the impact of these is generally limited compared to the loss of exclusivity on the active pharmaceutical ingredient.
• Launch of Generics: Generic versions of hydroxychloroquine sulfate became widely available globally following the expiry of key patents. For example, in the United States, generic versions have been available for many years.
• Market Impact of Expirations: The expiration of patents has directly led to:
  • Increased Competition: A proliferation of generic manufacturers entering the market.
  • Price Erosion: Significant price reductions due to competitive market forces.
  • Market Share Shift: A substantial shift in market share from the branded product (Plaquenil) to generic equivalents.

What are the Price Trends and Projections for Plaquenil?

Price trends for Plaquenil are characterized by a mature market with significant downward pressure from generic competition.

• Current Pricing:
  • Branded Plaquenil: While still available, branded Plaquenil typically commands a premium. However, its market share is declining in favor of generics. Pricing for branded Plaquenil can vary by region and insurance coverage, but wholesale acquisition costs can range from $0.50 to $2.00 per tablet for a 200 mg dose.
  • Generic Hydroxychloroquine Sulfate: Generic versions are significantly more affordable. Wholesale acquisition costs for generic hydroxychloroquine sulfate typically range from $0.05 to $0.30 per tablet for a 200 mg dose. This represents a more than 90% reduction compared to the branded product.
• Historical Price Trends: Since the widespread availability of generic options, the price of hydroxychloroquine sulfate has steadily declined. The introduction of multiple generic manufacturers intensified competition, driving prices to their current low levels.
• Factors Influencing Future Pricing:
  • Generic Competition: The primary determinant of future pricing will be the intensity of generic competition. An increase in the number of generic manufacturers or consolidation among them could lead to marginal price fluctuations, but substantial increases are unlikely.
  • Manufacturing Costs: Fluctuations in raw material costs and manufacturing efficiencies can have a minor impact on generic pricing.
  • Regulatory Landscape: Changes in regulatory requirements for generic drug approval or manufacturing standards could influence supply and, consequently, price.
  • Demand: While demand for established indications remains relatively stable, any significant shifts in treatment guidelines or the emergence of new, large-scale therapeutic uses (which is currently speculative) could alter demand dynamics. However, given the drug's profile and existing alternatives, major demand surges are not anticipated.
  • Supply Chain Stability: Disruptions in the global pharmaceutical supply chain, as seen in recent years, can temporarily impact availability and pricing, though this is usually short-lived for mature generics.
• Price Projections:
  • Short to Medium Term (1-5 years): Prices for generic hydroxychloroquine sulfate are expected to remain stable, with potential for marginal decreases due to ongoing competition. Branded Plaquenil prices may see minor adjustments but will likely continue to lose market share. The average price per tablet for generic hydroxychloroquine sulfate is projected to stay within the $0.05 to $0.35 range.
  • Long Term (5+ years): Pricing is unlikely to deviate significantly from current levels unless there are unforeseen market events or shifts in the therapeutic landscape. The drug is in a mature phase of its lifecycle, and its therapeutic niche is well-defined with established generic availability.

What is the Regulatory Status and Potential for New Indications?

The regulatory status of Plaquenil is tied to its approved indications, while exploration of new uses faces significant hurdles.

• Approved Indications and Regulatory Status:
  • United States: Approved by the Food and Drug Administration (FDA) for the treatment of malaria, rheumatoid arthritis, and discoid lupus erythematosus and systemic lupus erythematosus [2].
  • European Union: Authorized for use in rheumatoid arthritis, discoid lupus erythematosus, and systemic lupus erythematosus.
  • Other Regions: Approved in numerous other countries for similar autoimmune and antimalarial indications.
• Post-Market Surveillance: Regulatory bodies maintain ongoing surveillance for safety signals associated with hydroxychloroquine, particularly concerning ocular toxicity with long-term use.
• Exploration of New Indications:
  • COVID-19: During the initial phases of the COVID-19 pandemic, hydroxychloroquine was extensively investigated as a potential treatment. However, large-scale, robust clinical trials (e.g., the RECOVERY trial) demonstrated no significant benefit in reducing mortality or improving clinical outcomes in hospitalized patients with COVID-19 [3]. Regulatory agencies subsequently advised against its use for this indication outside of clinical trials.
  • Other Autoimmune Conditions: Research continues into its potential efficacy in other autoimmune or inflammatory conditions. However, new indications require extensive clinical trials to prove safety and efficacy. The bar for approval is high, especially with the availability of more targeted and potentially safer therapies.
  • Challenges for New Indications:
    • Lack of Clear Efficacy: Demonstrating a significant and consistent therapeutic benefit in new indications is challenging.
    • Safety Profile: Long-term ocular side effects and other potential adverse events require careful risk-benefit assessment.
    • Competition: Newer, more specific treatments often emerge during the lengthy development period for new indications of older drugs.
    • Cost of Development: The significant cost and time investment required for Phase II and III clinical trials may not be justifiable for a drug with an already mature and low-priced generic market, especially if the potential new market is not substantial or faces strong competition.
• Regulatory Hurdles for New Uses: Any company seeking to gain approval for a new indication would need to submit comprehensive data demonstrating clinical utility, safety, and a favorable risk-benefit profile to regulatory authorities like the FDA and EMA. This process typically involves multiple phases of clinical trials and can take several years.

What are the Key Growth Opportunities and Threats for Plaquenil?

The market for Plaquenil is characterized by a stable but mature core demand, with limited opportunities for significant growth and several potential threats.

• Growth Opportunities:
  • Emerging Markets Penetration: Increasing healthcare access and diagnostics in developing economies could lead to modest growth in demand for established treatments like hydroxychloroquine for its approved indications.
  • Repurposing Research (Limited Potential): While speculative, any breakthrough research demonstrating significant efficacy and safety in a novel, unmet medical need could create a new market segment. However, the probability of such a discovery leading to substantial market growth for hydroxychloroquine is low given its profile and existing alternatives.
• Threats:
  • Competition from Novel Therapies: The development of new, highly effective, and targeted biologic and small molecule therapies for RA and SLE poses a significant threat. These newer agents often offer improved efficacy and safety profiles, leading physicians to prescribe them over older, less specific drugs like hydroxychloroquine.
  • Generic Price Wars: Intense competition among generic manufacturers can lead to further price erosion, impacting profitability for all market participants.
  • Safety Concerns and Labeling Changes: Any new findings regarding long-term safety issues, particularly ocular toxicity, could lead to stricter prescribing guidelines, warnings, or even reduced use, negatively impacting demand.
  • Off-Label Use Scrutiny: Past controversies surrounding unproven uses have created a sensitive regulatory environment. Any resurgence of off-label promotion or use without robust clinical backing could invite regulatory action.
  • Treatment Guideline Evolution: Changes in clinical practice guidelines for RA and SLE that de-emphasize or discontinue hydroxychloroquine as a preferred second-line agent would directly reduce demand.

Key Takeaways

Plaquenil (hydroxychloroquine sulfate) operates in a mature market driven by its approved indications for rheumatoid arthritis and systemic lupus erythematosus. Patent expiries have facilitated widespread generic competition, leading to significant price erosion. The average price for generic hydroxychloroquine sulfate is projected to remain low, between $0.05 and $0.35 per tablet, with minimal expected fluctuation. Future market dynamics will be shaped by ongoing generic competition, evolving treatment guidelines, and the emergence of novel therapies for autoimmune diseases. While limited growth opportunities exist in emerging markets, the drug faces threats from superior therapeutic alternatives and potential safety-related regulatory actions.

Frequently Asked Questions

1. What is the primary market driver for Plaquenil in 2024? The primary market driver remains its established efficacy and physician familiarity in treating rheumatoid arthritis and systemic lupus erythematosus.

2. Will the price of generic hydroxychloroquine sulfate increase significantly in the next five years? No, significant price increases are not anticipated. The market is highly competitive, and pricing is expected to remain stable or experience marginal decreases.

3. Are there any new indications for Plaquenil currently undergoing late-stage clinical trials? As of the latest available data, there are no major new indications for Plaquenil in late-stage clinical trials that are expected to lead to significant market expansion. Research in potential new areas is ongoing but faces considerable hurdles.

4. How does the safety profile of Plaquenil compare to newer therapies for rheumatoid arthritis? Plaquenil has known safety concerns, notably ocular toxicity with long-term use. Newer therapies, particularly biologics, may offer different safety profiles and are often more targeted, potentially leading to fewer systemic side effects for specific patient populations.

5. What is the impact of Sanofi's patent expiry on the current market? Sanofi's patent expiry occurred many years ago, allowing for the broad introduction of generic hydroxychloroquine sulfate, which has fundamentally reshaped the market towards lower-cost generic alternatives.

Citations

[1] Grand View Research. (2023). Hydroxychloroquine Market Size, Share & Trends Analysis Report by Type, by Application, by Region, and Segment Forecasts, 2023 - 2030. [2] U.S. Food & Drug Administration. (n.d.). Approved Drug Products Database. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ [3] RECOVERY Collaborative Group. (2020). Hydroxychloroquine in patients admitted to hospital with COVID-19. The New England Journal of Medicine, 383(21), 2030-2042. doi:10.1056/NEJMoa2023186